Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations

This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with

  • 0 views
  • 17 Jan, 2021
  • 3 locations
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphomas or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists …

cytotoxic chemotherapy
stem cell transplant
interleukins
tazemetostat
nervous
  • 990 views
  • 17 Jan, 2021
  • 113 locations
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

This phase I study is designed to establish the safety, maximally tolerated dose (MTD) and recommended phase II dose (RP2D) of the ERK inhibitor ulixertinib (BVD-523) when combined with the CDK4

measurable disease
solid tumour
metastatic pancreatic cancer
neutrophil count
  • 63 views
  • 23 Jan, 2021
  • 1 location
Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas

Open-label dose escalation of Ulixertinib combined with fixed dose of hydroxychloroquine.

KRAS
carcinoma
measurable disease
adenocarcinoma
neutrophil count
  • 0 views
  • 25 Jan, 2021
  • 1 location
Ulixertinib in Treating Patients With Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or

antibody therapy
stem cell transplant
cytotoxic chemotherapy
interleukins
cytokines
  • 94 views
  • 18 Jan, 2021
  • 77 locations